NO20072214L - 6-(pyridinyl)-4-pyrimidonderivater som inhibitorer av tau-proteinkinase-1 - Google Patents

6-(pyridinyl)-4-pyrimidonderivater som inhibitorer av tau-proteinkinase-1

Info

Publication number
NO20072214L
NO20072214L NO20072214A NO20072214A NO20072214L NO 20072214 L NO20072214 L NO 20072214L NO 20072214 A NO20072214 A NO 20072214A NO 20072214 A NO20072214 A NO 20072214A NO 20072214 L NO20072214 L NO 20072214L
Authority
NO
Norway
Prior art keywords
protein kinase
pyridinyl
inhibitors
tau protein
pyrimidone derivatives
Prior art date
Application number
NO20072214A
Other languages
English (en)
Inventor
Fumiaki Uehara
Shinsuke Hiki
Kenji Fukunaga
Toshiyuki Kohara
Kazutoshi Watanabe
Satoshi Yokoshima
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Publication of NO20072214L publication Critical patent/NO20072214L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Forbindelse representert ved formel (I), en optisk aktiv isomer eller et farmasøytisk akseptabelt salt av denne: hvor R1 er et C1-C12-alkyl; R2 er hydrogenatom eller lignende; R3 er halogen eller lignende; q er et helt tall fra 1 til 7; R4 er halogen eller lignende; p er 0 eller et helt tall fra 1 til 5; R5 er et C6-C10-alkyl, en heteroring eller lignende; og X er oksygen, NH eller lignende; som anvendes for forhindring og/eller terapeutisk behandling av en sykdom forårsaket av t-proteinkinase 1-hyperaktivitet, så som neurodegenerative sykdommer (f.eks. Alzheimers sykdom).
NO20072214A 2004-09-29 2007-04-27 6-(pyridinyl)-4-pyrimidonderivater som inhibitorer av tau-proteinkinase-1 NO20072214L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004313115 2004-09-29
PCT/JP2005/018497 WO2006036015A2 (en) 2004-09-29 2005-09-29 6- (pyridinyl) -4-pyrimidone derivates as tau protein kinase 1 inhibitors

Publications (1)

Publication Number Publication Date
NO20072214L true NO20072214L (no) 2007-06-12

Family

ID=35848411

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072214A NO20072214L (no) 2004-09-29 2007-04-27 6-(pyridinyl)-4-pyrimidonderivater som inhibitorer av tau-proteinkinase-1

Country Status (25)

Country Link
US (1) US8129377B2 (no)
EP (3) EP2266969A3 (no)
JP (1) JP5186213B2 (no)
KR (1) KR20070057931A (no)
CN (1) CN101048397A (no)
AR (1) AR051823A1 (no)
AT (1) ATE499356T1 (no)
AU (1) AU2005288045B2 (no)
BR (1) BRPI0515851A (no)
CA (1) CA2581179A1 (no)
CY (1) CY1112326T1 (no)
DE (1) DE602005026546D1 (no)
DK (1) DK1805164T3 (no)
EA (1) EA013004B1 (no)
ES (1) ES2359071T3 (no)
IL (1) IL182223A0 (no)
MX (1) MX2007003722A (no)
NO (1) NO20072214L (no)
NZ (1) NZ554722A (no)
PL (1) PL1805164T3 (no)
PT (1) PT1805164E (no)
SI (1) SI1805164T1 (no)
TW (1) TWI354669B (no)
WO (1) WO2006036015A2 (no)
ZA (1) ZA200703383B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR050865A1 (es) * 2004-09-09 2006-11-29 Sanofi Aventis Derivados de 2- morfolino-4-pirimidona
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
TW200740779A (en) * 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
TW200813015A (en) * 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
ES2373587T3 (es) * 2006-08-23 2012-02-06 Pfizer Products Inc. Compuestos de pirimidona como inhibidores de gsk-3.
WO2008026046A1 (en) * 2006-08-30 2008-03-06 Pfizer Products Inc. Morpholine d3 dopamine antagonists
AR064660A1 (es) * 2006-12-26 2009-04-15 Mitsubishi Tanabe Pharma Corp Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras
PL2195293T3 (pl) 2007-08-22 2014-03-31 Astrazeneca Ab Pochodne cyklopropyloamidu
AR068439A1 (es) 2007-09-14 2009-11-18 Mitsubishi Tanabe Pharma Corp Derivado de 6-pirimidinil-pirimid-2-ona
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
JP5535310B2 (ja) * 2009-08-13 2014-07-02 田辺三菱製薬株式会社 タウプロテインキナーゼ１阻害剤としてのピリミドン誘導体
US20130005710A1 (en) 2009-11-18 2013-01-03 Tetsuya Tsukamoto Aminopyridine derivative
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
WO2011102794A1 (en) 2010-02-18 2011-08-25 Astrazeneca Ab Processes for making cyclopropyl amide derivatives and intermediates associated therewith
US9365539B2 (en) 2010-05-11 2016-06-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
US9580407B2 (en) 2012-12-07 2017-02-28 Merck Sharp & Dohme Corp. Regioselective N-2 arylation of indazoles
EP3615513B1 (en) 2017-04-24 2022-07-20 Tesaro, Inc. Methods of manufacturing of niraparib
CN111138412B (zh) * 2018-11-06 2023-09-15 上海奕拓医药科技有限责任公司 一种螺芳环化合物及其应用
CN111704611B (zh) * 2019-07-25 2022-01-14 上海凌达生物医药有限公司 一类芳基螺环类shp2抑制剂化合物、制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI241298B (en) * 1998-09-25 2005-10-11 Mitsubishi Chem Corp Pyrimidone derivatives
EP1136482A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
EP1136483A1 (en) 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-[Piperazinyl]pyrimidone derivatives
AU2002337499B2 (en) * 2001-09-21 2007-08-23 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
MXPA04002661A (es) 2001-09-21 2004-11-22 Sanofi Aventis Derivados de pirimidona 4, 3-sustituida.
EP1454908B1 (en) * 2003-03-07 2008-02-27 Sanofi-Aventis Substituted pyridinyl-2-(diaza-bicyclo-alkyl)-pyrimidinone derivatives
TWI357408B (en) 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives

Also Published As

Publication number Publication date
JP5186213B2 (ja) 2013-04-17
CY1112326T1 (el) 2015-12-09
EP1805164B9 (en) 2011-09-07
CN101048397A (zh) 2007-10-03
ZA200703383B (en) 2009-05-27
AU2005288045A1 (en) 2006-04-06
TWI354669B (en) 2011-12-21
ATE499356T1 (de) 2011-03-15
EA200700756A1 (ru) 2007-10-26
EP1805164A2 (en) 2007-07-11
AU2005288045B2 (en) 2011-08-18
MX2007003722A (es) 2007-05-23
CA2581179A1 (en) 2006-04-06
JP2008514587A (ja) 2008-05-08
EP2261224A2 (en) 2010-12-15
IL182223A0 (en) 2007-09-20
AU2005288045A2 (en) 2008-05-29
BRPI0515851A (pt) 2008-08-12
US8129377B2 (en) 2012-03-06
US20090239864A1 (en) 2009-09-24
PT1805164E (pt) 2011-04-11
EA013004B1 (ru) 2010-02-26
NZ554722A (en) 2010-07-30
EP2266969A3 (en) 2011-02-16
EP2261224A3 (en) 2011-02-16
DE602005026546D1 (de) 2011-04-07
EP2266969A2 (en) 2010-12-29
WO2006036015A3 (en) 2006-06-01
PL1805164T3 (pl) 2011-07-29
WO2006036015A2 (en) 2006-04-06
EP1805164B1 (en) 2011-02-23
TW200626573A (en) 2006-08-01
ES2359071T3 (es) 2011-05-18
KR20070057931A (ko) 2007-06-07
SI1805164T1 (sl) 2011-05-31
DK1805164T3 (da) 2011-05-16
AR051823A1 (es) 2007-02-14

Similar Documents

Publication Publication Date Title
NO20072214L (no) 6-(pyridinyl)-4-pyrimidonderivater som inhibitorer av tau-proteinkinase-1
NO20071787L (no) 2-morfolin-4-pyrimidonforbindelse
NO20084302L (no) 2-(syklisk amino)-pyrimidonderivater som TPK1-inhibitorer
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20073926L (no) Pyrazolforbindelser som modulerer aktivitet av CDK-, GSK- og aurorakinaser
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20070907L (no) Pyrrolo-pyridin kinase modulatorer
NO20054952L (no) 2,3,6-trisubstituerte 4-pyrimidonderivater
NO20090202L (no) Prolylhydroksylaseinhibitorer
NO20064726L (no) Imidazolforbindelser for behandling av neurodegenerative forstyrrelser
NO20062370L (no) Amidderivater
NO20073859L (no) Pyrrolopyrazoler, potente kinaseinhibitorer
NO20070258L (no) Benzyltriazolonforbindelser som ikke-nukleoside revers transkriptase inhibitorer
HRP20050533A2 (en) Aminoindazole derivatives and use thereof as kinase inhibitors
NO20073170L (no) Kaspaseinhibitorer og anvendelse derav
NO20082496L (no) Pyrazinderivater
NO20063449L (no) Substituerte heterocykler og deres anvendelse
NO20092759L (no) 2-substituerte-6-heterosykliske pyrimidonderivater som tauproteinkinase-1-inhibitorer
NO20054330L (no) 8-substituerte-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
NO20054331L (no) Substituerte-8-perfluoralkyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
NO20064344L (no) Caspaseinhibitorer og anvendelser derav
NO20071314L (no) Peptidiske vasopressinreseptoragonister
EA201070366A1 (ru) 3-метил-2-((2s)-2-(4-(3-метил-1,2,4-оксадиазол-5-ил)фенил)морфолино)-6-(пиримидин-4-ил)пиримидин-4(3н)-он в качестве ингибитора тау-протеинкиназы
NO20061045L (no) Imidazolderivater
NO20060718L (no) Substituerte tiofoner og deres anvendelse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application